课题基金 / 基金详情

Clinical impact of unbound-base pharmacokinetics of active metabolites of a tyrosine kinase inhibitor regorafenib

Clinical impact of unbound-base pharmacokinetics of active metabolites of a tyrosine kinase inhibitor regorafenib
酪氨酸激酶抑制剂瑞戈非尼活性代谢物的未结合碱药代动力学的临床影响
批准号:
19K07204
负责人:
Fujita Ken-ichi
金额:
$2.83万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2019
资助国家:
日本
项目状态:
已结题
起止时间:
2019-04-01 至 2023-03-31

项目摘要

项目成果

Fujita Ken-ichi的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
Regorafenib-induced erythema multiforme is associated with HLA-C*01:02 and HLA-B*46:01 in Japanese cancer patients
日本癌症患者中瑞戈非尼诱导的多形红斑与 HLA-C*01:02 和 HLA-B*46:01 相关
DOI: --
发表时间: 2021
期刊:
影响因子: --
作者: [Natsumi Matsumoto, Kosuke Takeshima, Yutaro Kubota, Hiroo Ishida, Takuya Taunoda, Yasutsuna Sasaki, Ken-ichi Fujita]
通讯作者: Ken-ichi Fujita
Adeno-associated virus-mediated knockdown demonstrates the major role of hepatic Bcrp in the overall disposition of the active metabolite of the tyrosine kinase inhibitor regorafenib in mice.
腺相关病毒介导的敲除证明了肝脏 Bcrp 在小鼠体内酪氨酸激酶抑制剂瑞戈非尼活性代谢物的总体处置中的主要作用。
DOI: 10.1016/j.dmpk.2022.100483
发表时间: 2023
期刊: Drug Metab Pharmacokinet
影响因子: --
作者: [Al-Shammari AH, Masuo Y, Yoshino S, Yamashita R, Ishimoto T, Fujita K, Kato Y.]
通讯作者: Kato Y.
Associations of polymorphisms in CCL4L1 with regorafenib-induced hand-foot skin reaction in colorectal cancer patients.
CCL4L1 多态性与结直肠癌患者瑞戈非尼诱导的手足皮肤反应的关联。
DOI: --
发表时间: 2023
期刊:
影响因子: --
作者: [Koutaro Ono, Remi Murase, Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Takuya Tsunoda, Yasutsuna Sasaki, Ken-ichi Fujita]
通讯作者: Ken-ichi Fujita
High unbound plasma concentration of M-2, an active metabolite, is associated with shorter survival in patients with metastatic colorectal cancer who received regorafenib
M-2(一种活性代谢物)的未结合血浆浓度较高,与接受瑞戈非尼治疗的转移性结直肠癌患者的生存期较短有关
DOI: --
发表时间: 2019
期刊:
影响因子: --
作者: [Yutaro Kubota, Ken-ichi Fujita, Takehiro Takahashi, Yu Sunakawa, Hiroo Ishida, Kazuyuki Hamada, Wataru Ichikawa, Takuya Tsunoda, Yusuke Masuo, Yukio Kato, Yasutsuna Sasaki]
通讯作者: Yasutsuna Sasaki
7
    Development of catalytic reactions towards a realization of a hydrogen society
    • 批准号:
      19H02715
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.15万
    • 财政年份:
      2019
    • 负责人:
      Fujita Ken-ichi
    • 依托单位:
    Regulation of drug efflux pump's activities and gene expression by drug-induced oxidative stress
    • 批准号:
      16K08299
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.08万
    • 财政年份:
      2016
    • 负责人:
      Fujita Ken-ichi
    • 依托单位:
    Mechanisms of delayed elimination and decreased plasma protein binding of anticancer drugs which are mainly eliminated via the liver in cancer patients with severe renal failure
    • 批准号:
      26460205
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.16万
    • 财政年份:
      2014
    • 负责人:
      Fujita Ken-ichi
    • 依托单位:
    Enhancement of magnetically recoverable transition metal catalysts by the introduction of hydrophobic field